Overview

* Enliven reports Q3 net loss of $20.1 mln, down from $23.2 mln last year

* Company maintains strong cash position with $478 mln

* Completed Phase 1b of ENABLE trial, plans Phase 3 trial in 2026

Outlook

* Company plans to initiate Phase 3 trial of ELVN-001 in 2026

* Enliven expects cash runway to extend into first half of 2029

Result Drivers

* RESEARCH AND DEVELOPMENT EXPENSES: R&D expenses were $18.2 million for the third quarter of 2025, compared to $21.3 million for the third quarter of 2024.

* GENERAL AND ADMINISTRATIVE EXPENSES: G&A expenses were $6.9 million for the third quarter of 2025, compared to $5.8 million for the third quarter of 2024.

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$20.15

Income mln

Q3 Basic -$0.32

EPS

Q3 -$25.10

Income mln

From

Operatio

ns

Q3 $25.10

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Enliven Therapeutics Inc ( ELVN ) is $38.00, about 48.3% above its November 11 closing price of $19.64

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)